Residential treatment exclusively for smoking cessation in patients with Crohn’s disease: Results from a pilot study

• Published in: Tobacco induced diseases 2022-06, Vol.20 (June), p.1-4
• Main Authors: Leifert, Jens, Schulz, Cornelia, Engler, Uta
• Format: Article
• Language: English
• Subjects: Behavior modification; Carbon monoxide; Cigarette smoking; Crohn's disease; Drug addiction; Drug dependence; Feasibility; Group dynamics; Hospitals; Motivation; Nicotine; Patients; pilot study; Public health; residential treatment; Risk analysis; Risk factors; Short Report; Smoking; Smoking cessation; Therapy
• ISSN: 1617-9625; 2070-7266; 1617-9625
• DOI: 10.18332/tid/149481

Introduction: Cigarette smoking is a risk factor for the induction and severity of the course of Crohn’s disease (CD). Hospital admission may be required for treatment of the disease but is generally not available solely for smoking cessation. Outpatient group therapy is readily available, however long-term quit rates are limited. Residential treatment for smoking cessation may offer a more intense contact between patient and therapist, and may result in higher abstinence rates in a sensitive group of patients. The objective of this pilot study is to evaluate the feasibility of implementing a residential program with hospital admission, exclusively for smoking cessation for patients suffering from CD. Material and Methods: Twelve eligible smokers suffering from CD were recruited for a 9-day inpatient smoking cessation treatment. Treatment consisted of single and group behavioral therapy together with supportive measures such as exercise therapy, relaxation techniques or nutritional counselling. Nicotine replacement therapy or prescription medication was offered according to the Fagerström test for nicotine dependence (FTND) score and treatment guidelines. Quit rates were assessed by CO-testing during hospital treatment and by follow-up calls 6 months after discharge. Results: All recruited participants arrived on time for treatment and collectively stopped smoking on the 2nd day after admission. All participants completed the therapy process without relapse and left the hospital smoke-free (100% quit rate on discharge, CO monitored). Self-reported abstinence rates after 6 months were 72.7% for continuous abstinence and 81.8% for 7-day point prevalence abstinence. Conclusions: Residential treatment exclusively for smoking cessation is feasible and efficient and may be a valuable treatment option for patients suffering from CD.